GlassScriptPhysician profile
William D Curtis
NPI 1568437424
$5,481.52
in general payments reported to CMS, 2019-2025
31 companies · $81.07 in 2025
The $81.07 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $549 · 2021: $792 · 2022: $1,178 · 2023: $866 · 2024: $1,123 · 2025: $81.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050 · Education: $19.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.48 |
| Education | $19.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,531.39 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,161.91 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $612.58 | 2019-2024 | |
| Janssen Biotech, INC. | $533.73 | 2019-2024 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $258.01 | 2020-2024 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $183.89 | 2019-2024 | Entyvio, Gattex |
| Genzyme Corporation | $154.04 | 2022-2025 | |
| Gilead Sciences, INC. | $145.54 | 2021-2024 | |
| Celgene Corporation | $95.90 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $92.63 | 2020-2024 | Linzess |
| Ucb, INC. | $91.90 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $72.50 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $66.60 | 2019 | |
| Ferring Pharmaceuticals INC. | $58.76 | 2021-2023 | Rebyota |
| Boston Scientific Corporation | $58.36 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.20 | 2019-2024 | Dificid |
| Organon LLC | $29.91 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $25.65 | 2024 | Dupixent |
| Allergan, INC. | $24.91 | 2019 | |
| Dova Pharmaceuticals | $24.28 | 2019 | |
| Phathom Pharmaceuticals, INC. | $23.66 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $22.86 | 2024 | Iqirvo |
| Lilly USA, LLC | $22.27 | 2024 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $19.64 | 2021 | |
| Celltrion USA INC. | $19.44 | 2024 | Zymfentra |
| Zimmer Biomet Holdings, INC. | $18.84 | 2024 | A.L.P.S. |
| Ardelyx, INC. | $17.17 | 2024 | Ibsrela |
| Shionogi INC | $16.84 | 2019 | |
| Redhill Biopharma INC. | $15.36 | 2021 | |
| Amgen INC. | $15.21 | 2023 | Avsola, Amjevita |
| Braintree Laboratories, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.